MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

Bayer AG

Închisă

SectorFinanțe

21.29 -0.37

Rezumat

Modificarea prețului

24h

Curent

Minim

20.405

Maxim

21.835

Indicatori cheie

By Trading Economics

Venit

3.9B

-328M

Vânzări

1.8B

12B

P/E

Medie Sector

30.9

22.015

EPS

1.05

Randament dividend

0.49

Marjă de profit

-2.796

Angajați

90,587

EBITDA

615M

1.7B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+25.54% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.49%

3.90%

Statistici piață

By TradingEconomics

Capitalizare de piață

422M

22B

Deschiderea anterioară

21.66

Închiderea anterioară

21.29

Sentimentul știrilor

By Acuity

26%

74%

87 / 542 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Bayer AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 mar. 2025, 09:37 UTC

Principalele dinamici ale pieței

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 mar. 2025, 11:21 UTC

Câștiguri

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 mar. 2025, 08:45 UTC

Câștiguri

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 mar. 2025, 07:26 UTC

Câștiguri

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 apr. 2025, 09:27 UTC

Acțiuni populare

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mar. 2025, 08:38 UTC

Market Talk

Bayer's Partial Recovery Is in Sight -- Market Talk

5 mar. 2025, 13:39 UTC

Market Talk
Câștiguri

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 mar. 2025, 13:26 UTC

Market Talk

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 mar. 2025, 08:30 UTC

Market Talk
Câștiguri

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 mar. 2025, 06:41 UTC

Câștiguri

Bayer Launches Plan to Boost Profitability at Crop Science

5 mar. 2025, 06:40 UTC

Câștiguri

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 mar. 2025, 06:39 UTC

Câștiguri

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 mar. 2025, 06:39 UTC

Câștiguri

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 mar. 2025, 06:36 UTC

Câștiguri

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 mar. 2025, 06:35 UTC

Câștiguri

Bayer Guidance is on a Currency Adjusted Basis

5 mar. 2025, 06:34 UTC

Câștiguri

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 mar. 2025, 06:34 UTC

Câștiguri

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 mar. 2025, 06:33 UTC

Câștiguri

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 mar. 2025, 06:33 UTC

Câștiguri

Bayer Sees 2025 Sales EUR45B-EUR47B

5 mar. 2025, 06:32 UTC

Câștiguri

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer 4Q Net Loss EUR335M

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 mar. 2025, 06:31 UTC

Câștiguri

Bayer 4Q Sales EUR11.73B

13 ian. 2025, 21:05 UTC

Top știri

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 ian. 2025, 15:06 UTC

Achiziții, Fuziuni, Preluări

Bayer Didn't Disclose Financial Details

9 ian. 2025, 15:05 UTC

Achiziții, Fuziuni, Preluări

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 ian. 2025, 15:05 UTC

Achiziții, Fuziuni, Preluări

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Comparație

Modificare preț

Bayer AG Așteptări

Obiectiv de preț

By TipRanks

25.54% sus

Prognoză pe 12 luni

Medie 26.89 EUR  25.54%

Maxim 33 EUR

Minim 22 EUR

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBayer AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

10 ratings

1

Cumpărare

9

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 22.575Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

87 / 542 Clasament în Finanțe

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.